Researchers from Johns Hopkins University demonstrate that tumour-derived DNA fragments can be detected in blood samples more than three years before clinical cancer diagnosis, by advanced genome sequencing technology. The team around Yuxuan Wang identified genetic signatures from microscopic tumours that shed infinitesimal amounts of DNA into the bloodstream, just like finding needles in molecular haystacks.
The breakthrough lies in detecting tiny DNA fragments that tumours release into our bloodstream. These genetic whispers, invisible to conventional tests, can now be identified more than three years before diagnosis. Consequently, this research outcome can potentially transform cancer treatment from a reactive into a preventable condition, which might save millions of lives through early intervention when treatments are most effective and least invasive. By detecting disease years before symptoms appear, hospitals and the healthcare systems can provide accessible, quality cancer care to broader populations worldwide.
Research article:
Lambda Biologics’ Oncology Solutions: Patient-derived cancer organoid-based drug evaluation service
Gastric Cancer Organoid | Breast Cancer Organoid | Hepatocarcinoma Cancer Organoid | Pancreatic Cancer Organoid
